AIM ImmunoTech Inc

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AIM ImmunoTech reports promising clinical progress and financial stability

AIM ImmunoTech demonstrated strong clinical progress and financial stability, positioning the company well for future growth and potential partnerships.
While facing regulatory and operational challenges, the company's focus on expanding Ampligen's therapeutic applications and medical expertise presents significant opportunities for advancement.
Investors should monitor AIM ImmunoTech's continued progress in clinical trials and regulatory interactions, as positive outcomes could drive value creation and market expansion.

AIM ImmunoTech reports positive clinical progress and solid financial standing

AIM ImmunoTech's Q2 2024 Earnings Call highlighted significant progress in clinical trials for Ampligen, particularly in oncology indications.
Financially, the company maintains a solid cash position and continues to manage expenses to support ongoing operations and future milestones.
While facing challenges in trial design and cost management, AIM ImmunoTech remains well-positioned to capitalize on opportunities for growth and partnership.

AIM ImmunoTech advances Ampligen with positive clinical data amid challenges

AIM ImmunoTech's Q3 showcased progress in Ampligen's development, with promising data supporting its therapeutic potential. While facing financial challenges, the company is focused on leveraging opportunities for collaborations and commercialization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AIM ImmunoTech Inc (NYSE:AIM) has announced what it calls positive preliminary pilot study data from its ongoing Expanded Access Program (EAP) evaluating its investigational drug Ampligen as a therapeutic for Long COVID. The immuno-pharma firm said the preliminary data from this uncontrolled clinical trial found that patients reported statistically significant improvements in chronic fatigue after treatment with Ampligen and, based on these early results, the company is working to move forward with a Phase 2 controlled trial.

AIM ImmunoTech reveals positive pilot study data from EAP evaluating Ampligen for treatment of Long COVID

Growing body of data supports Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions Growing body of data supports Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions

AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

AIM ImmunoTech Inc (NYSE: AIM) reported follow-on data from its published single-center named patient program.  For the study, patients with locally advanced pancreatic cancer (LAPC) or metastatic disease were treated following FOLFIRINOX.

AIM ImmunoTech Posts Additional Patient Data From Pancreatic Cancer Study

AIM ImmunoTech Inc (NYSE:AIM) reported promising follow-on data from its previously published single-center named patient program evaluating its flagship drug candidate Ampligen (rintatolimod) as maintenance therapy for pancreatic cancer. For the study, patients with locally advanced pancreatic cancer or metastatic disease were treated following FOLFIRINOX (a chemotherapy combination used to treat pancreatic cancer), said the company.

AIM ImmunoTech hails positive data from program evaluating Ampligen as maintenance therapy for pancreatic cancer

Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC)

AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data

Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions – Including a Potential Hostile Takeover of the Company – and Prevent Group from Continued Violations of Federal Securities Laws and SEC and Florida Injunctions

AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid

Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July 25th at 8:30 AM ET Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July 25th at 8:30 AM ET

AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series

AIM ImmunoTech Inc (NYSE:AIM) announced that it has entered into a lease agreement with the New Jersey Economic Development Authority for a 5,210 square foot research and development (R&D) facility at the state-supported New Jersey Bioscience Center (NJBC). The immuno-pharma company said the incubator at North Brunswick, New Jersey, which is designed for small businesses in the region, is dedicated to life sciences and biotechnology companies, and the NJBC has invested over $70 million in facilities and improvements to its campus.

AIM ImmunoTech inks lease deal for new state-of-the-art product development and testing facility in New Jersey

Company enters into a lease agreement with the state-supported New Jersey Bioscience Center at North Brunswick, one of the nation's leading business incubators dedicated to life sciences and biotechnology Company enters into a lease agreement with the state-supported New Jersey Bioscience Center at North Brunswick, one of the nation's leading business incubators dedicated to life sciences and biotechnology

AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing

AIM ImmunoTech Inc (NYSE:AIM) revealed that the Netherlands Patent Office (Octrooicentrum Nederland) has issued Patent No 2027383 - a utility patent - covering Ampligen (rintatolimod) and other dsRNA products developed by the company for use in the prevention, or treatment of coronavirus (COVID-19), with a base patent term extending until 2041. The Ocala, Florida-based immuno-pharma company's RNA product candidate is being developed for globally important cancers, viral diseases and disorders of the immune system.

AIM ImmunoTech boosts intellectual property with new Netherlands utility patent covering Ampligen and dsRNA products aimed at COVID-19

Further expansion of patent portfolio supports of the Company's extensive Ampligen research program across multiple types of cancers and viral diseases, including COVID-19 in the Netherlands Further expansion of patent portfolio supports of the Company's extensive Ampligen research program across multiple types of cancers and viral diseases, including COVID-19 in the Netherlands

AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or Prevention

AIM ImmunoTech Inc (NYSE:AIM) has announced that it is working towards filing an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for its long COVID investigational drug Ampligen, partly based on positive early data from its ongoing clinical trial.   The company said it had amended its ongoing FDA-authorized AMP-511 trial to enroll four post-COVID patients with new onset myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) following acute COVID-19.

AIM ImmunoTech to file Investigational New Drug application for Ampligen to treat long COVID

- First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continued positive data in ovarian and triple-negative breast cancer clinical studies as well as clinical potential with checkpoint inhibitors

AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update

OCALA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced it will participate in the Solve M.E. Diagnostics signature event “Long COVID: Research, Policy, and Economic Impact,” being held virtually and in New York, N.Y. on Thursday, May 19, 2022.

AIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact' on May 19, 2022

AIM ImmunoTech Inc (NYSE:AIM) has provided a summary of positive clinical data supporting the synergistic potential of its flagship drug Ampligen (rintatolimod) with checkpoint blockade therapies. In a statement, AIM ImmunoTech CEO Thomas Equels said: “We have amassed a growing body of encouraging Ampligen data to date through close collaborations with leading KOLs at preeminent institutions.

AIM ImmunoTech says Ampligen data supports synergistic potential with checkpoint blockade therapies

Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors

AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies

AIM ImmunoTech Inc (NYSE:AIM). has engaged Amarex Clinical Research LLC to manage the Phase 2 study of its flagship drug candidate Ampligen as a therapy for locally advanced pancreatic cancer (AMP-270), with clinical trial on track to start in the third quarter of this year.

AIM ImmunoTech engages CRO Amarex Clinical Research to manage Phase 2 of Ampligen study

- Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer

AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc (NYSE:AIM) presented positive data from its ongoing Phase 2a clinical study at the Roswell Park Comprehensive Cancer Center evaluating its flagship drug Ampligen (rintatolimod) as a component of a Chemokine Modulatory (CKM) regimen for the treatment of colorectal cancer metastatic to the liver at the six-day annual meeting of the American Association for Cancer Research (AACR), which kicked off on April 8, in New Orleans, Louisiana. The Ocala, Florida-based immuno-pharma company said the research was led by Roswell Park medical oncologist Sarbajit Mukherjee, in collaboration with senior investigator Pawel Kalinski, who is the chair of I=immunology at Roswell Park.

AIM ImmunoTech reports positive data from Phase 2a study evaluating Ampligen as part of a regimen treating colorectal cancer that has spread to the liver

Genocea Biosciences

Hoth Therapeutics

What you need to know about trading penny stocks on April 11th The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes

AIM ImmunoTech Inc (NYSE: AIM) has announced the presentation of positive data from a Phase 1 study of Ampligen in metastatic triple-negative breast cancer. The pre-determined primary efficacy endpoint was met (increase in CD8⍺ in TME).

AIM ImmunoTech Shares Jump On Positive Data From Ampligen Study In Breast Cancer Setting

Phase 1 study of metastatic triple-negative breast cancer using chemokine modulation (CKM) therapy, including Ampligen and pembrolizumab, successfully met primary endpoint

AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer

Primary endpoint of the study was met, evidenced by increased CD8a expression post-treatment (p=0.046)

AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen® as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver

AIM ImmunoTech Inc (NYSE:AIM) said it has a “strong” balance sheet that will fund operations and clinical development programs through 2023.  In a statement reporting its financial results for 2021, the Florida-based company said it ended the year with cash and cash equivalents of $48.3 million as it advances its flagship drug candidate Ampligen (rintatolimod) to treat cancers, viral diseases and disorders of the immune system.

AIM ImmunoTech reports ‘strong' balance sheet to fund operations and clinical development programs through 2023

- Year marked by continued execution across clinical development programs and the continued establishment of a growing body of positive data with Ampligen® in multiple high-value indications

News for AIM ImmunoTech Inc Stock (AIM)